By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


TRACON Pharmaceuticals, Inc. 

4510 Executive Drive
Suite 330
San Diego  California  92121  U.S.A.
Phone: 858-550-0780 Fax: 858-550-0786



Company News
TRACON Pharma (TCON) Announces Positive Results From NCI Phase I/II Trial Of TRC105 And Nexavar In Hepatocellular Cancer Published In Clinical Cancer Research 8/16/2017 7:06:11 AM
TRACON Pharma (TCON) Reports Second Quarter Financial Results And Provides Corporate Update 8/9/2017 1:37:43 PM
TRACON Pharma (TCON) To Report Second Quarter Company Highlights And Financial Results On August 8, 2017 8/2/2017 1:35:42 PM
TRACON Pharma (TCON) Doses First Patient In Phase I/II Study Of TRC253 In Patients With Prostate Cancer 5/24/2017 10:34:10 AM
TRACON Pharma (TCON) Announces Publication In Blood Of Preclinical Data Indicating Activity Of TRC105 In Acute Myeloid Leukemia And B-Cell Acute Lymphoblastic Leukemia 5/12/2017 11:25:26 AM
TRACON Pharma (TCON) Reports First Quarter Financial Results And Provides Corporate Update 5/11/2017 11:49:17 AM
TRACON Pharma (TCON) Announces $21 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC 3/15/2017 10:42:14 AM
TRACON Pharma (TCON) Reports Fourth Quarter And Year-End 2016 Financial Results And Provides Corporate Update 3/1/2017 12:10:13 PM
TRACON Pharma (TCON) Announces First Patient Dosed In Phase III TAPPAS Trial Of TRC105 In Angiosarcoma 2/16/2017 8:22:35 AM
TRACON Pharma (TCON) Announces Top-Line Results From NCI-Sponsored Phase 2 Trial Of TRC105 In Recurrent Glioblastoma 2/10/2017 8:49:11 AM